Table 1 Anti-nephrin autoantibodies in patients with podocytopathies (MCD and FSGS) [3, 6–10]
Study | No. of participant | Age | Female:Male | Positve rate of anti-nephrin autoantibodies |
|---|---|---|---|---|
Hengel et al. [3] | MCD: 105 | MCD: 47 (35–62) | MCD: 38:67 | MCD: 44% |
pFSGS: 74 | pFSGS: 52 (37–60) | pFSGS: 21:53 | pFSGS: 9% | |
Watts et al. [6] | 62 | 16 (5.5–37.5) | 27:35 | 29% |
Chebotareva et al. [7] | MCD: 11 | MCD: 36.5 (25.8–47.8) | MCD: 7:4 | MCD: 91% |
pFSGS: 32 | pFSGS: 36 (27–56) | pFSGS: 21:20 | pFSGS: 68.8% | |
Shirai et al. [8] | gFSGS: 8 | gFSGS: 12.3 (9.2–15.5) | gFSGS: 4:4 | gFSGS: 0% |
pFSGS: 14 | pFSGS: 10.4 (6.9–12.8) | pFSGS: 4:10 | pFSGS: 85.7% | |
MCD: 13 | MCD: N.A. | MCD: N.A. | MCD: 38.0% | |
Batal et al. [9] | rDP: 22 | rDP: 38 (30–45) | rDP: 19:20 | rDP: 38% |
nrDP; 17 | nrDP: 29 (26–56) | nrDP: 12:5 | nrDP: 0% | |
Raglianti et al. [10] | MCD: 50 | MCD: 20.6 (1.8–72.6) | MCD: 22:28 | MCD: 48.0% |
FSGS: 58 | FSGS: 22.7 (0.25–78.5) | FSGS: 26:32 | FSGS: 22.4% | |
CG: 2 | CG: 11.2 (10.25–12.16) | CG: 1:1 | CG: 50.0% |